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The transcribed pseudogene RPSAP52 enhances
the oncofetal HMGA2-IGF2BP2-RAS axis through
LIN28B-dependent and independent let-7 inhibition
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One largely unknown question in cell biology is the discrimination between inconsequential
and functional transcriptional events with relevant regulatory functions. Here, we ﬁnd that the
oncofetal HMGA2 gene is aberrantly reexpressed in many tumor types together with its
antisense transcribed pseudogene RPSAP52. RPSAP52 is abundantly present in the cytoplasm,
where it interacts with the RNA binding protein IGF2BP2/IMP2, facilitating its binding to
mRNA targets, promoting their translation by mediating their recruitment on polysomes and
enhancing proliferative and self-renewal pathways. Notably, downregulation of RPSAP52
impairs the balance between the oncogene LIN28B and the tumor suppressor let-7 family of
miRNAs, inhibits cellular proliferation and migration in vitro and slows down tumor growth
in vivo. In addition, high levels of RPSAP52 in patient samples associate with a worse prog-
nosis in sarcomas. Overall, we reveal the roles of a transcribed pseudogene that may display
properties of an oncofetal master regulator in human cancers.
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The largest part of the mammalian genome is transcribedinto RNA species with little or no coding potential, knownas noncoding RNAs (ncRNAs)1. Although their biological
roles are still largely unknown, a growing number of long non-
coding RNAs (lncRNAs, a label arbitrarily assigned to transcripts
longer than 200 nucleotides) display regulatory properties by
acting at all levels in gene expression control (from epigenetic
modiﬁcations and chromatin dynamics to the control of post-
transcriptional messenger RNA stability and translation)2,3. In
some cases, their key functions in normal homeostasis and
development links the dysregulation of their expression with
causal roles in cancer4, and there are instances of lncRNAs
involved in each of the cancer hallmarks, including sustained
proliferative signaling and growth (e.g., ANRIL5, lincRNA-p216,
MEG37), invasion and metastasis (e.g., HULC8, MALAT19,
HOTAIR10), resistance to cell death (e.g., PCGEM111), and
replicative immortality (e.g., TERC12, TERRA13). Mechanisms of
action include the interaction with other nucleic acids and/
or protein factors, which confers the ability to function as
scaffolds, guides, decoys, or allosteric regulators of several
nuclear or cytoplasmic processes14,15. In a growing number of
examples, their roles intertwine with that of the better-
studied miRNAs16, either by cooperating in their function17 or
by impairment of the miRNA-mediated regulation18. The latest
annotation in GENCODE estimates that up to 16,000 genes in the
human genome correspond to lncRNAs, and a similar number
is given to pseudogenes (https://www.gencodegenes.org/stats/
current.html#). Although some pseudogenes do code for pro-
teins, the majority are thought to be lncRNAs owing to the
accumulation of mutations in the deﬁnition of the open reading
frames, and as such their biological functions include the ability
to regulate gene expression similarly to lncRNAs19, and are
thereby also involved in growth-regulatory roles in cancer20.
RPSAP52 is a pseudogene-transcribed RNA that runs antisense
to the oncofetal gene HMGA2, a transcriptional co-regulator that
is expressed at high levels during embryonic development,
silenced in virtually all adult tissues and re-expressed in several
human cancers, where its levels are generally associated with the
presence of metastases and poor prognosis21,22. Our previous
results indicate that RPSAP52 positively regulates HMGA2
expression through the formation of an R loop structure23.
Herein we further study the role of this transcribed pseudogene in
breast and sarcoma tumors, and uncover its role as a pro-growth
factor through the regulation of the IGF2BP2/IGF1R/RAS axis
and the balance between LIN28B and let-7 levels.
Results
RPSAP52 impacts on IGF2BP2 and let-7 in breast cancer cells.
We have previously uncovered the positive impact of the expres-
sion of the pseudogene RPSAP52 on its sense, protein-coding gene
HMGA2 (Fig. 1a)23. Both genes are generally expressed at low
levels in differentiated normal tissues and overexpressed in a
number of human cancers, including breast cancer, concomitant
with a hypomethylation of the associated CpG island (Fig. 1b). In
breast cancer patients, a positive correlation between the expres-
sion of both genes is observed (Fig. 1c), as is also seen in the NCI60
panel of cell lines (Supplementary Fig. 1a). Other studies have
reported that high HMGA2 expression predicts poor outcome in
breast cancer patients25. Since our observations indicate that
knockdown of RPSAP52 results in a reduction in HMGA2
expression23, we decided to look further into the molecular
mechanism of RPSAP52-mediated regulation of the locus. A panel
of breast cancer cell lines was used to conﬁrm the presence of
RPSAP52 transcript by semi-quantitative PCR (Fig. 1d). Surpris-
ingly, most cell lines expressed the annotated RPSAP52 transcript
(Refseq NR_026825.2) together with an additional species that
corresponds to the inclusion of a 104-nucleotides-long internal
exon (Fig. 1d and Supplementary Fig. 1b). Evidence as to the
presence of this alternative exon in the spliced transcript can also
be found in the MiTranscriptome database24, which catalogs long
polyadenylated RNA transcripts (www.mitranscriptome.org, with
reference G018828|T081486). The quantitative measurement of
expression levels indicates that HMGA2 mRNA and the two iso-
forms of RPSAP52 are 2-3 orders of magnitude overexpressed
when there is hypomethylation of the promoter-associated CpG
island, as shown with Illumina’s HumanMethylation450 BeadChip
analysis (Fig. 1e) and was conﬁrmed by bisulﬁte sequencing at the
nucleotide level (Supplementary Fig. 1c). Altogether, these obser-
vations conﬁrm the coordinate expression of both genes and their
silencing in hypermethylated conditions. RPSAP52 is annotated as
a noncoding RNA in Refseq, but is labeled as coding in some
coding potential calculator tools. Pseudogenes are more likely to
give false positive results in programs such as PhyloCSF (since they
are similar to their parental protein-coding, and PhyloCSF evalu-
ates conservation to predict coding capacity). We thus conducted
in vitro transcription/translation assays, which conﬁrmed the
absence of RPSAP52 coding potential (Supplementary Fig. 2a).
However, analysis of RNA presence along sucrose gradients from
MCF10A cells showed the presence of RPSAP52 transcripts in
polysomal fractions, indicating a role in translation. Interestingly, a
strong correlation in co-sedimentation of HMGA2 mRNA and
RPSAP52 transcript was observed (Supplementary Fig. 2b–e).
Indeed, further characterization of RPSAP52 transcripts showed
that they are enriched in the cytoplasm (Fig. 1f) and poly-
adenylated (Fig. 1g), suggesting additional roles besides the ability
to regulate HMGA2 transcription in the nucleus. In order to
identify protein partners of RPSAP52 that could help characterize
its activity, we performed RNA pull-down assays combined with
mass spectrometry (MS). In vitro synthesized full-length RPSAP52
RNA was incubated in the presence of MCF10A extracts and the
retrieved proteins were analyzed by SDS-PAGE. As shown in Fig.
2a, a protein band of ~70 kDa is speciﬁcally pulled-down by
RPSAP52 RNA, but not by its antisense sequence or another
unrelated RNA. This band was characterized by MS, which iden-
tiﬁed two proteins within the isolated fragment: the insulin-like
growth factor 2 mRNA-binding protein 2 (IGF2BP2), also known
as IMP2 (from which seven peptides were identiﬁed), and the
heterogeneous nuclear ribonucleoprotein Q (HNRNPQ), also
known as SYNCRIP (identiﬁed with six peptides) (Supplementary
Fig. 3a). IGF2BP2, together with IGF2BP1 and IGF2BP3 partakes
of a family of RNA binding proteins that have been implicated in
post-transcriptional control, including the regulation of mRNA
localization, stability, and translation26. Similar to HMGA2,
although the expression of IGF2BPs is normally restricted to
embryonic stages, they are re-expressed upon malignant trans-
formation, playing roles in the maintenance of cancer stem cells
and the promotion of tumor growth27. Western blot with speciﬁc
antibodies conﬁrmed that both IGF2BP2 and HNRNPQ are
enriched in the RPSAP52 pull-down, and analysis of RPSAP52
truncates indicate that the two isoforms are able to bind to these
two factors (Fig. 2b). In accordance with the pull-down results, the
previously reported consensus binding site for IGF2BP2, the
CAUH (H=A, C, U) motif28, is abundant along the two con-
stitutive RPSAP52 exons, but absent on the alternative exon
(Supplementary Fig. 3b), suggesting that the alternative splicing
event does not impact on the afﬁnity of the binding.
IGF2BP2 is a direct transcriptional target of HMGA229 and
both proteins partake of a pro-proliferative axis30,31 that
interweaves with the function of let-7 family of miRNAs. Both
HMGA2 and IGF2BP2 mRNAs are direct targets of let-7, but
IGF2BP proteins have been suggested to modulate let-7 action via
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the formation of cytoplasmic mRNPs that would protect certain
mRNAs from let-7 binding and repression32,33. The most
abundantly expressed members of the family are let-7a/b/e in
MCF10A cells, and let-7a/d/f/g/i in Hs578T cells (Supplementary
Fig. 3c). Interestingly, the levels of the mature form of these
miRNAs were upregulated in RPSAP52-depleted cells, both in
MCF10A and Hs578T clones stably expressing shRNAs (Fig. 2c
and Supplementary Fig. 3g) and in cells transiently expressing
three different locked nucleic acid (LNA)-based antisense
oligonucleotides (ASOs) gapmers (Fig. 2e). RPSAP52 has a region
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of homology with other RPSA pseudogenes, but none was affected
by our depletion strategy (Supplementary Fig. 3d). Also, given the
possibility that some pseudogenes regulate parental gene expres-
sion, we analyzed the levels of RPSA protein in the RPSAP52-
depleted cells, but no quantitative change was found (Supple-
mentary Fig. 3e). Of note, gapmer-mediated depletion of HMGA2
increased both RPSAP52 isoforms and resulted in a decrease in
let-7 levels, suggesting that the negative regulation exerted by
RPSAP52 on the miRNAs is not through HMGA2 pathway (Fig.
2e). Let-7 regulates IGF2BP2 mRNA and other members of
IGF1 signaling pathway, among others IGF1R and RAS. Down-
regulation of RPSAP52 with shRNAs or gapmers reduces the
amount of these proteins, in accordance with the increased let-7
levels (Fig. 2d, f and Supplementary Fig. 3g, h). LIN28A and
LIN28B are the main negative regulators of let-7 biogenesis,
through direct binding to either pre-let-7 and/or pri-let-734,35, but
often only one of the two proteins is found expressed in human
cancer cell lines36. We could not detect LIN28B protein
expression in MCF10A cells, and LIN28A was not altered upon
RPSAP52 knockdown (Supplementary Fig. 3f), suggesting that
changes in let-7 in MCF10A cells were not consequences of
impaired biogenesis at the level of regulation by LIN28. However,
RPSAP52-mediated regulation of IGF2BP2 protein levels is
reverted by overexpression of LIN28B, indicating a convergence
on the same regulatory network (Fig. 2g).
Next, the phenotypic impact of the altered control of the
IGF2BP2/IGF1R/RAS pathway by RPSAP52 was tested both
in vitro and in vivo.
RPSAP52 has oncogenic-like features in vitro and in vivo. Upon
RPSAP52 knockdown, all three breast cell lines tested (the non-
transformed MCF10A and the tumorigenic Hs578T and HCC1143
cells) proved to be signiﬁcantly less proliferative in the sulforho-
damine B (SRB) assay (Fig. 3a), and had a signiﬁcantly lower
percentage colony formation density than control cells (Fig. 3b).
Interestingly, RPSAP52 depletion was also associated with a
decreased migration potential (Fig. 3c). High levels of let-7 miRNAs
often correlate with a lower capacity for self-renewal and plur-
ipotency. Given the observed reduction in proliferation and
migration following RPSAP52 knockdown, we next assessed the
levels of markers of cell stemness (Fig. 3d). NANOG and OCT4
protein levels were decreased in RPSAP52-depleted cells, suggesting
this lncRNA promotes features of cancer stem cells. This was fur-
ther conﬁrmed in soft-agar colony formation experiments, in which
the measure of the anchorage-independent growth of the cells
showed a signiﬁcant decrease upon depletion of RPSAP52 (Fig. 3e).
For the in vivo approach, we next used tumor formation assays in
nude mice. MCF10A and Hs578T cells stably expressing either
scrambled shRNAs or shRNAs against RPSAP52 were sub-
cutaneously injected into mice, and the tumor formation and
volume was monitored. Tumors originating from RPSAP52
knockdown cells had a signiﬁcantly lower volume and weight at end
point than control tumors, both for the non-tumorigenic and the
tumorigenic cells (Fig. 3f, g). Importantly, the amount of RAS and
IGF2BP2 proteins were markedly reduced in the excised tumors at
end point, indicating that the in vitro ﬁndings were maintained in
the in vivo context (Fig. 3f, g).
RPSAP52 regulates IGF2BP2/LIN28B/let-7 axis in sarcoma. We
next attempted to determine whether RPSAP52-mediated reg-
ulation of proliferative pathways occurred in other cancer types.
The analysis of the collection of human cancers available from
The Cancer Genome Atlas (TCGA) indicates HMGA2 and
RPSAP52 expression is specially increased in adrenocortical car-
cinoma, mesothelioma and in the sarcoma samples available (as
measured by Z-score, Supplementary Fig. 4a). TCGA RNA
expression and DNA methylation data showed that RPSAP52
promoter hypermethylation was associated with transcript
downregulation across sarcoma samples (Fig. 4a, upper panel;
Pearson correlation, r2= 0.264, P-value= 4.764e–10). Of note,
HMGA2 expression in the same samples shows a poorer corre-
lation (Supplementary Fig. 4b, r2= 0.131, P-value= 2.582e–05).
Both genes maintain a positive expression correlation (Fig. 4a,
lower panel) and a difference of ~1–2 orders of magnitude in
their relative expression (Supplementary Fig. 4c). This is in
agreement with absolute quantiﬁcation of RPSAP52 and HMGA2
transcripts in MCF10A and A673 cell lines, in which HMGA2
mRNA is 1–2 orders of magnitude at higher levels (Supplemen-
tary Fig. 4d). Since the HMGA2-IGF2BP2-RAS pathway has been
previously involved in the pathogenesis of embryonic rhabdo-
myosarcoma31, we then assessed HMGA2 and RPSAP52 expres-
sion in a panel of cell lines derived from rhabdomyosarcoma and
also Ewing’s sarcoma (Fig. 4b). Both RPSAP52 isoforms were
abundantly expressed in most rhabdomyosarcoma cell lines, with
just one order of magnitude higher HMGA2 expression in Rh28,
Rh41, or CW9019 cells. In Ewing’s sarcoma, RPSAP52 was gen-
erally lowly expressed with the exception of A673 cell line. We
thus focused on A673 cells to further characterize the molecular
function of this lncRNA. As seen in MCF10A cells, RNA pull-
downs conﬁrmed the ability of RPSAP52 to interact with
IGF2BP2 and SYNCRIP/HNRNPQ (Fig. 4c). Importantly, stable
clones expressing two different shRNAs against both RPSAP52
isoforms resulted in a strong increase in let-7 family members
(Fig. 4d, upper panel), even when HMGA2 levels were only
Fig. 1 Characterization of RPSAP52 expression in breast cancer. a Intronic/exonic organization of sense/antisense transcripts in HMGA2 locus. Coordinates
are referred to the UCSC Genome Browser (GRCh38/hg38 release). Only the 5′ regions of HMGA2 transcripts are included. b Box plot representations
show both HMGA2 and RPSAP52 transcripts are overexpressed in a variety of human cancers compared with normal controls (TCGA dataset) (upper
panels), concomitant with hypomethylation of the associated CpG island (lower panels). On each box plot, the central mark indicates the median, and the
bottom and top edges indicate the interquartile range (IQR). The box plot whiskers represent either 1.5 times the IQR or the maximum/minimum data point
if they are within 1.5 times the IQR. P-values are according to the two-tailed Wilcoxon signed-rank test. c Pearson correlation between HMGA2 and
RPSAP52 transcripts in breast cancer primary tumors (all stages included). Normalized values of RNA-seq data from TCGA are represented. d Semi-
quantitative RT-PCR to detect the expression of HMGA2 and RPSAP52 in a panel of breast cancer cell lines. Detection of RPSAP52 transcripts was done with
primers that detect both isoforms. e Upper panel: heatmap representation of the DNA methylation proﬁle for the CpG island-containing promoter at the
HMGA2 locus, as analyzed with the 450K DNA methylation microarray. Single CpG methylation levels are shown. Green, unmethylated; magenta,
methylated. Data from 11 breast cancer cell lines are shown. Lower panel: the expression levels of both RPSAP52 (including or excluding the alternative
exon) and HMGA2 were analyzed by RT-qPCR and represented relative to MCF7 cell line. Graphs represent the means of three replicates from different
RNA extractions ±SD. f Nuclear/cytoplasmic fractionation of MCF10A cells, analyzed by RT-qPCR and western blot to assess fraction purity. Graphs
represent the mean ±SD of two replicates of fractionation. g Poly(A)+/poly(A)− partition of total RNA from MCF10A cells and analysis by RT-qPCR.
Primers that detect the RPSAP52+altex isoform were used. Graphs represent the mean ±SD of two replicates of poly(A) selection. Source data are
provided as a Source Data ﬁle
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Fig. 2 RPSAP52 interacts with IGF2BP2 and HNRNPQ and inﬂuences proliferative pathways in MCF10A cells. a RNA pull-down assay to detect RPSAP52-
associated proteins. In vitro synthesized full-length RPSAP52 transcript (including the alternative exon) or control sequences (the antisense transcript and
the unrelated Uc.160+ RNA) were tested. The proteins retrieved were analyzed by SDS-PAGE and the band of ~70 kDa indicated by the arrow was
identiﬁed by MS as containing IGF2BP2 and HNRNPQ. b Western blot showing the association between RPSAP52 RNA and IGF2BP2 and HNRNPQ
proteins. Different truncated fragments of RPSAP52 RNA (as shown in the upper diagram) were incubated in the presence of MCF10A total protein extracts
and the pulled-down material was subject to western blot with speciﬁc antibodies. Total extract from the MCF10A cell lines was used as input control, and
a reaction without RNA (beads) as negative control. c Stable knockdown of RPSAP52 results in upregulation of let-7 family of miRNAs. Total RNA from
MCF10A clones constitutively expressing two different shRNAs against RPSAP52 (sh1 or sh4) was analyzed by RT-qPCR to assess HMGA2 mRNA,
RPSAP52 transcripts and let-7 miRNAs levels. Graphs represent the mean ±SD of three independent RNA extractions. Two-tailed student t-test were used
(*P < 0.05, **P < 0.01, ns= not signiﬁcant). d Western blot to analyze IGF2BP2, IGF1R, and RAS protein levels upon stable knockdown of RPSAP52
transcripts. e Transient transfection of MCF10A cells with locked nucleic acid (LNA)-based antisense oligonucleotides (ASOs) gapmers targeting HMGA2
mRNA (HMGA2), exon1 (RPSAP52 Ex) or the ﬁrst intron (RPSAP52 RL1 and RL2) of RPSAP52 transcript. Expression levels of HMGA2, RPSAP52 and let-7
were measured by RT-qPCR. Graphs represent the mean ±SD of seven independent replicates (for HMGA2 and RPSAP52) or three replicates (for let-7).
Two-tailed student t-test were used (*P < 0.05, **P < 0.01, ***P < 0.001). f Western blot to analyze IGF2BP2 and RAS protein levels upon transient
knockdown of RPSAP52 transcripts. g Western blot to analyze IGF2BP2 and RAS protein levels upon transient overexpression of LIN28B protein in the
background of RPSAP52 depletion. Source data are provided as a Source Data ﬁle
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moderately reduced (Fig. 4d, lower panel). In this case, RPSAP52
knockdown did not correlate with IGF2BP2 decrease, but with a
marked reduction in LIN28B protein levels, which in contrast to
breast cell lines, is abundantly expressed in A673 cells (Fig. 4e and
Supplementary Fig. 4e). Also, while RAS levels were only partially
reduced, downstream signaling was impaired, as observed by the
decrease in p-ERK levels (Fig. 4e). In an in vivo setting, and
similarly to the observations in breast cell lines, this results in a
marked reduction in tumor formation when mice are sub-
cutaneously injected with RPSAP52-depleted A673 cells (Fig. 4f).
SRB viability/cytotoxicity assay
0
20
40
60 scr
sh4 D8
sh4 C9
sh4 F7
Hs578T
***
Time (days)
R
el
 a
bs
or
ba
nc
y
R
el
 a
bs
or
ba
nc
y
SRB viability/cytotoxicity assay
0
10
20
30
40 scr
sh4 C3
sh4 E2
sh4 D11
HCC1143
***
Time (days)
a
b
sc
r
sh
1 
F7
sh
4 
E9
sh
4 
C7
NANOG
β-ACTIN
OCT4
β-ACTIN
SOX2
β-ACTIN
0 20 40 60 80
0
100
200
300
400 scr
sh4 E9
sh1 F7
***
***
MCF10A
Time (days)
T
um
or
 v
ol
um
e 
(m
m
3 )
T
um
or
 v
ol
um
e 
(m
m
3 )
scr sh4 E9
0
50
100
150
200
250
***
T
um
or
 w
ei
gh
t (
m
g)
T
um
or
 w
ei
gh
t (
g)
sc
r
sh
4 
E9
IGF2BP2
RAS
β-ACTIN
scr D8 C9 F7
sh4 clones
IGF2BP2
β-ACTIN
c d e
f
sc
r
sh
1 
F7
sh
4 
E9 sc
r
sh
1 
F7
sh
4 
E9
0
50
100
150
Exp 1 Exp 2
MCF10A
***
***
***
***
S
ur
vi
vi
ng
 fr
ac
tio
n
SRB viability/cytotoxicity assay
1 4
0
50
100
150 scr
sh1 F7
sh4 E9
sh4 C7
MCF10A
sh4 F4
****
Time (days)
R
el
 a
bs
or
ba
nc
y
sc
r
sh
4 
D8
sh
4 
C9
sh
4 
F7 sc
r
sh
4 
D8
sh
4 
C9
sh
4 
F7
0
50
100
150
Exp 1 Exp 2
Hs578T
**
***
** *
**
*S
ur
vi
vi
ng
 fr
ac
tio
n
S
ur
vi
vi
ng
 fr
ac
tio
n
sc
r
sh
4 
C3
sh
4 
E2
sh
4 
D1
1 sc
r
sh
4 
C3
sh
4 
E2
sh
4 
D1
1
0
50
100
150
Exp 1 Exp 2
**
**
* ** ** **
HCC1143
g
0 10 20 30
0
1000
2000
3000
4000
scr
sh4 F7
sh4 D8
sh4 C9
*
Hs578T
Time (days)
sc
r
sh
4 
D8
sh
4 
C9
sh
4 
F7
0
1
2
3
4
5
***
***
*
Transwell - crystal violet staining
scr sh1 F7 sh4 E9
0.
00
3.
11
5.
62
8.
12
10
.6
2
13
.1
2
15
.6
3
18
.1
3
20
.6
3
23
.1
4
0
1
2
3
4
scr
sh1 F7
sh4 E9
C
el
l i
nd
ex **
**
Migration assay
Time (hours)
sc
r
sh
4 
E9
sh
1 
F7
scr D8 C9 F7
sh4 clones
sc
r
sh
1 
F7
sh
4 
E9
sh
4 
C7
sh
4 
F4
0
50,000
100,000
150,000
200,000
Clonogenicity assay
***
R
F
U
2 3 5 6 7 1 42 3 5 6 7 1 42 3 5 6 7
50
40
50
40
80
50
40
80
20
40
80
40
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11910-6
6 NATURE COMMUNICATIONS |         (2019) 10:3979 | https://doi.org/10.1038/s41467-019-11910-6 | www.nature.com/naturecommunications
Interestingly, LIN28B protein reduction is only partially
explained by a decrease in LIN28B mRNA levels (Supplementary
Fig. 4f). This discrepancy, together with the interaction detected
between RPSAP52 and IGF2BP2, and the presence of RPSAP52
along sucrose gradient’s heavy fractions, which correspond to
translating poly-ribosomes (see text above and Supplementary
Fig. 2d), prompted us to investigate the possibility that LIN28B
levels were regulated by the lncRNA at the translational level.
RPSAP52 modulates IGF2BP2 binding to its mRNA targets.
IGF2BP2 is a mRNA stability and translational regulator with
some well-described targets, such as IGF237, NRAS31, or
HMGA138. The closely related IGF2BP1 protein has been shown to
interact with LIN28B mRNA and increase LIN28B protein levels in
ES-2 cells32. In order to assay the interaction of IGF2BP2 with
LIN28B mRNA in A673 cells, we carried out protein immuno-
precipitation followed by RT-qPCR of the pulled-down RNA. We
could conﬁrm the interaction of IGF2BP2 with both RPSAP52
isoforms, with IGF2BP2 and NRAS mRNA, and importantly, with
LIN28B mRNA. Of note, even though the RPSAP52 isoform
lacking the alternative exon is more abundant in A673 cells, both
transcripts were recovered in comparable amounts in IGF2BP2
immunoprecipitate, with a ~10-fold higher afﬁnity of IGF2BP2 for
RPSAP52+ altex RNA (Fig. 5a, see RT-qPCR). Further, LIN28B
protein was not co-immunoprecipitated with IGF2BP2 protein
(Fig. 5b), suggesting its putative regulation by IGF2BP2 is at the
level of transcript. We next wanted to test the possibility that this
binding is regulated by RPSAP52 presence. Interestingly, whereas
binding to IGF1R and IGF2BP2 mRNAs was not altered, binding
of IGF2BP2 to LIN28B mRNA was reduced upon stable knock-
down of RPSAP52 (Fig. 5c). This suggests that this lncRNA might
regulate LIN28B post-transcriptionally through modulation of
IGF2BP2 function. In view of this, we decided to characterize in a
transcriptome-wide manner the IGF2BP2-RNA interactions with
individual nucleotide resolution (iCLIP-seq) under control or
RPSAP52-knockdown conditions. We identiﬁed 290,060 and
131,729 iCLIP-tags in control and RPSAP52-depleted A673 cells,
corresponding to 3075 and 1639 peak regions, respectively (Sup-
plementary Fig. 5a, b). As has been shown before, IGF2BP2 iCLIP
tags were enriched in 3′UTRs28,33, with ~60% of the iCLIP peaks
falling within 3′UTRs in control cells. Remarkably, knockdown of
RPSAP52 resulted in a speciﬁc decrease in the number of 3′UTR
peaks revealed by iCLIP and an increase in intronic regions (Fig.
5d). Motif enrichment analysis around the crosslinking-induced
truncation sites (CITS) indicate that the previously described
CAUH (H=A, C, U) consensus binding site28 also ranks high in
our iCLIP experiments, but is more enriched in the control samples
(Supplementary Fig. 5c, d). We found 1775 and 810 peaks with the
CAUH motif in the control and depleted sample, respectively,
representing a statistically signiﬁcant difference in occurrence
(Fisher’s exact test P-value= 5.286e–08). In addition, the number
of peaks with more than one CAUH motif was higher in the
control cells (average number of motifs was 1.81 for control and
1.64 for depleted cells; Mann–Whitney U test, P-value=
1.786e–05). The full list of statistically signiﬁcant iCLIP-seq peaks
and CITS can be found in Supplementary Data 1. Differences in
motif binding and the reduction in 3′UTR recognition results in a
shortlist of 34 transcripts with differential IGF2BP2 iCLIP counts
along their 3′UTR (Fig. 5e). GO enrichment analysis shows these
genes belong to categories that may relate to IGF2BP2 involvement
in cancer invasion and metastasis, including cell-substrate adhe-
sion, spreading, and wound healing, as well as the canonical
function for IGF2BP2 pathway, cellular glucose homeostasis (Fig.
5e). Of note, previous CLIP experiments for IGF2BPs in plur-
ipotent stem cells have revealed that cell adhesion is also the most
signiﬁcant GO category for CLIP-enriched 3′UTRs for IGF2BP139.
This suggests that the levels of RPSAP52 have a dramatic impact on
IGF2BP2 global role. In addition, top ten GO categories for genes
with signiﬁcant iCLIP peaks present on their 3′UTRs in the control
sample correspond to signaling pathways and cell cycle progres-
sion, whereas none of these categories are enriched in the
RPSAP52-depleted sample (Fig. 5f).
Previous CLIP-seq studies with IGF2BP2 had revealed
binding sites on the 3′UTR of LIN28B mRNA in
HEK293T cells28, and we detected similar sites in our
experimental setting and a tendency to decrease upon RPSAP52
depletion, although without any statistical power (Fig. 5g). For
other validated IGF2BP2 targets, such as HMGA2, we also
detected abundant iCLIP signal corresponding to direct binding
of IGF2BP2 to its 3′UTR. In this case, binding is dramatically
lost upon RPSAP52 knockdown (Fig. 5h), and a corresponding
decrease in HMGA2 protein level is observed (Supplementary
Fig. 5e). This is not a general phenomenon for all IGF2BP2
targets, since other well-characterized mRNA partners, such as
HMGA1, NRAS, and IGF1R maintain comparable iCLIP signals
in both control and RPSAP52-depleted conditions (Supple-
mentary Fig. 5f). Our results thus suggest a speciﬁc loss of
IGF2BP2 afﬁnity for particular mRNA targets. Several of the
best characterized IGF2BP2 targets are regulated by let-7 (e.g.,
RAS, HMGA2…) but, interestingly, we could not ﬁnd a
differential presence of let-7 miRNA recognition motifs along
the 3′UTRs of the immunoprecipitated mRNAs in control or
depleted samples (Fisher’s exact test P-value= 0.8974). Also,
Fig. 3 RPSAP52 displays oncogenic features in breast cancer cells. a Viability/cytotoxicity assays in MCF10A, Hs578T and HCC1143 clones. The experiment
was performed three times and one representative graph is shown for each cell line. Values are mean ±SD of n≥ 6 measurements. One-way ANOVA was
used (***P < 0.001, ****P < 0.0001). b Effect of RPSAP52 silencing on colony formation ability. Representative plates are shown. Colonies were counted
from three replicate plates and two independent experiments. Values are mean ±SD. Two-tailed unpaired t-test were used (*P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001). c Migration capacity of RPSAP52-depleted clones was monitored over 24 h (n= 5 replicates per condition), with higher cell index
indicating higher migration. Values are mean ±SD. A two-tailed Mann–Whitney U test of data at end point was used (**P < 0.01). Inset: migration was also
assessed with transwells. Scale bar= 100 µm. d Western blot analysis of NANOG, OCT4, and SOX2 in RPSAP52-depleted cells. e The clonogenic ability
was assessed with at least n= 12 replicates per condition. Values are mean ±SD. A two-tailed Mann–Whitney U test was used (***P < 0.001). f Growth-
inhibitory effect of RPSAP52 knockdown in MCF10A mice xenografts. Upper graph: tumor volume (n= 10) was monitored over time. Mean values are
shown ±SEM. Lower graph: tumors were excised and weighed at 77 days (***P < 0.001, two-tailed Mann–Whitney U test). Western blot was carried out
from sh4 tumors since no material could be recovered from sh1 tumors, and the levels of RAS and IGF2BP2 proteins were analyzed. The photograph shows
the relative size of all tumors extracted. Scale bar= 10 mm. g Growth-inhibitory effect of RPSAP52 knockdown in Hs578T mice xenografts. Upper graph:
tumor volume (n= 9 for scr and n= 10 for sh4 clones) was monitored over time. Mean values are shown ±SEM. Lower graph: tumors were excised and
weighed at 28 days (*P < 0.05, ***P < 0.001, two-tailed Mann–Whitney U test). Western blot was carried out from tumors at end point and the levels of
IGF2BP2 protein were analyzed. The photograph shows the relative size of all tumors extracted. Scale bar= 10 mm. Source data are provided as a Source
Data ﬁle
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depletion of LIN28B does not impact on IGF2BP2 levels or its
binding to mRNA targets, indicating that the regulation of
RPSAP52 on IGF2BP2 does not proceed through LIN28B
(Supplementary Fig. 5h–j). Both HMGA2 and LIN28B mRNAs
are present at high levels upon RPSAP52 depletion (Fig. 4d and
Supplementary Fig. 4f), and their half-lives are not substantially
altered (Supplementary Fig. 5g), pointing to a decrease in their
translation as a consequence of a diminished binding to IGF2BP2.
RPSAP52 controls IGF2BP2 and mRNA distribution on
polysomes. To obtain direct evidence of the changes in transla-
tion efﬁciency for speciﬁc IGF2BP2 targets, we analyzed the
Ex1 Ex2altex
IGF2BP2 IGF2BP2
HNRNPQ
R
PS
AP
52
  e
xp
re
ss
io
n 
(Lo
g2
)
20
15
10
5 r 2 = 0.264
p = 4.764e–10
n = 129
0
0.0 0.1 0.2 0.3 0.4 0.5
Methylation
R
PS
AP
52
  e
xp
re
ss
io
n 
(Lo
g2
)
20
15
10
5
0
15.0 17.5 20.0 22.5
HMGA2 expression (Log2)
A6
73
EW
7
TC
71
TC
25
2
ST
AE
T1 Rh
1
RD
ES
SK
ES
1
A4
57
3
Rh
4
Rh
28
Rh
41
Rh
30
CW
90
19
RM
S1
3 RDRh
36
Ru
ch
2
A2
04
0
2
4
6
8 RT-qPCR HMGA2
R
el
at
iv
e
e
xp
re
ss
io
n
R
el
at
iv
e
e
xp
re
ss
io
n
A6
73
EW
7
TC
71
TC
25
2
ST
AE
T1 Rh
1
RD
ES
SK
ES
1
A4
57
3
Rh
4
Rh
28
Rh
41
Rh
30
CW
90
19
RM
S1
3 RDRh
36
Ru
ch
2
A2
04
0.00
0.05
0.10
0.15
0.20
0.25 RPSAP52 + altex
RPSAP52 – altex
RT-qPCR
Ewing sarcoma Rhabdomyosarcoma
A6
73
EW
7
TC
71
TC
25
2
ST
AE
T1
Rh
1
Rh
4
Rh
28
Rh
41
Rh
30
CW
90
19
RM
S1
3
RD Rh
36
Ru
ch
2
A2
04
H2
O
Ewing sarcoma cell lines Rhabdomyosarcoma cell lines
+ altex
– altex
*
RPSAP52
HMGA2
GAPDH
IGF2BP2,
HNRNPQ
M Be
ad
s
Ex
1 +
 al
tex
Ex
1
alt
ex
Do
m2
Do
m3
RNA immunoprecipitation
Be
ad
s
Ex
1 +
 al
tex
Ex
1
alt
ex
Do
m2
Do
m3
Western blotting
IGF2BP2
HNRNPQ
scr D6 E4 F7 G8 B9 B11 C9 D9 E8
0
5
10
20
40
60
A673
let-7a
let-7b
let-7e
Re
la
tiv
e 
ex
pr
es
sio
n
Re
la
tiv
e
 
ex
pr
es
sio
n
scr D6 E4 F7 G8 B9 B11 C9 D9 E8
0.0
0.5
1.0
1.5 HMGA2
RPSAP52 + altex
RPSAP52 – altex
Clones sh1 Clones sh4
IGF2BP2
LIN28B
RAS
p-ERK
ERK
NUCLEOLIN
scr E4 G8 B9 B11
sh1 sh4
Tu
m
or
 w
ei
gh
t (g
)
scr sh3 F9
0
1
2
3
4
a b
c
d e f
scr
sh3
Time (days)
Tu
m
or
 v
ol
um
e 
(m
m3
)
0 5 10 15 20 25
0
1000
2000
3000
scr
sh3 F9
A673
250
150
100
400
r 2 = 0.122
p = 4.99e–05
n = 129
225
150
102
76
52
38
31
24
17
12
102
76
52
38
102
76
52
102
40
40
20
25
80
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11910-6
8 NATURE COMMUNICATIONS |         (2019) 10:3979 | https://doi.org/10.1038/s41467-019-11910-6 | www.nature.com/naturecommunications
distribution of mRNAs across sucrose gradients in control or
RPSAP52-depleted A673 cells. We observed no major changes in
the polysome proﬁles of cells depleted of RPSAP52 when com-
pared with control cells, indicating that RPSAP52 knockdown
does not alter the global translational output of the cell (see
gradient proﬁles in Fig. 6a–d and Supplementary Fig. 6a). Sur-
prisingly, we detected a remarkable decrease in the amount of
HMGA2 and LIN28B mRNAs associated with polysomes (Fig. 6a,
b), indicating a selective regulation in their translation as a
function of RPSAP52 expression. This was not observed for NRAS
and GAPDH mRNAs (Fig. 6c, d). Analysis of total HMGA2,
LIN28B, and NRAS mRNAs under the same conditions does not
justify the speciﬁc redistribution of HMGA2 and LIN28B across
the gradients (Fig. 6e). These results indicate that the loss of
binding to IGF2BP2 previously observed in iCLIP experiments
correlates with lower translational efﬁciency for individual
mRNAs, and we next asked whether IGF2BP2 protein itself is
redistributed across the gradient. Importantly, even though
IGF2BP2 coimmunoprecipitates with the same protein partners
in pull-down experiments (Supplementary Fig. 6b, c), its co-
sedimentation with translating poly-ribosomes is markedly
reduced upon RPSAP52 knockdown (Fig. 6f), demonstrating that
RPSAP52 expression mediates the recruitment of IGF2BP2 on
polysomes. Taken together, the results suggest that the absence of
the pseudogene decreases the recruitment of IGF2BP2 to large
polysomes, thereby impacting on the translation of speciﬁc
mRNAs.
RPSAP52 alters key pathways and is a biomarker in sarcoma.
The inﬂuence of RPSAP52 on IGF2BP2 binding afﬁnity to its
multiple mRNA targets might reﬂect the impact of this pseudogene
on the control of several cellular processes. To identify such pro-
cesses we interrogated general gene expression with an expression
microarray platform under conditions of RPSAP52 knockdown by
shRNAs. As shown in Fig. 7a, 1% of the ~30,000 interrogated
Entrez Gene RNAs were downregulated following knockdown, and
0.7% of the transcripts were upregulated. In agreement with a
regulation mainly at the level of translation, none of the genes with
differential IGF2BP2 binding along the 3′UTR, as seen by iCLIP-
seq, is deregulated in the expression array analysis, indicating
that (i) the differential binding observed is not a consequence of
altered transcript expression, and (ii) none of the IGF2BP2 targets
whose interaction with this protein is inﬂuenced by RPSAP52
see their stability signiﬁcantly altered as a consequence. However,
they might participate in similar cellular pathways, since GO terms
analysis indicated that the subset of downregulated genes
was enriched in components of response to stimulus and
signaling, whereas upregulated genes appeared more involved in
development (Fig. 7a). The full list of altered transcripts (fold
change > 2, unpaired t-test P-value < 0.05) can be found in Sup-
plementary Data 2. Among the downregulated genes, molecular
functions that were overrepresented included genes involved in
receptor binding and growth factor activity (e.g., TIAM1, STYK1,
AREG, MICB) and sulfur compound binding (CYR61 and
MGST1). Of note, MGST1 is involved in the glutathione metabo-
lism pathway and a marker of Ewing’s sarcoma prognosis40, high
levels of NPY (a direct target of the EWS-FLI1 fusion) promotes
the metastasis of Ewing’s sarcoma models in vivo41, CRABP1 and
CPT1C favor tumor malignancy42,43, and CD109 and PTPRZ1 are
highly expressed in several cancer types (including sarcoma cell
lines44) and promote stem cell-like properties45. Among the
upregulated genes, genes involved in cytoskeletal protein binding
were enriched and included MTSS1, a regulator of actin dynamics
whose loss increases metastatic potential in a number of cancer
types46,47 (Supplementary Fig. 7a). The results from the expression
arrays were validated by RT-qPCR under conditions of depletion
of RPSAP52 where HMGA2 levels are largely unaffected (probably
because the R-loop forming, nuclear RPSAP52 is not effectively
depleted by shRNAs), and with two different shRNAs that target
distant regions on RPSAP52 transcripts (Fig. 7b and Supplemen-
tary Fig. 7b). These results indicate that RPSAP52 depletion implies
a decrease in proliferative and self-renewal programs and suggests
its potential as a biomarker in human samples. In support of this,
patients with high RPSAP52 expression levels had poorer prognosis
than cases with low expression in the sarcoma patients cohort from
TCGA database, whereas HMGA2 expression did not show any
prognostic effect in the same cohort (Fig. 7c). Since RPSAP52
expression negatively correlates with hypermethylation of the
associated CpG island (Fig. 4a), methylation itself is also a marker
of better prognosis (Fig. 7d), reinforcing the relevance of con-
sidering lncRNA expression regulation in translational medicine.
Taken together, our results suggest that the pseudogene
RPSAP52 controls the HMGA2/IGF2BP2/LIN28B axis through
a double mechanism that involves, in the nucleus, the positive
transcriptional regulation of HMGA2, and in the cytoplasm, the
regulation of the function of IGF2BP2 protein as a translational
co-regulator (among others, of LIN28B and HMGA2 mRNAs),
which in turn results in a downregulation of let-7 miRNAs and
derepression of their pro-proliferative targets (see diagram
depicting our working model in Fig. 7e). RPSAP52 thus displays
characteristics of an oncogenic gene whose dysregulation might
contribute to the progression of a number of human cancers.
Discussion
The detailed mechanism by which lncRNAs may contribute to
altering the output of signal transduction pathways is largely
Fig. 4 RPSAP52 is abundantly expressed in sarcoma and regulates the LIN28B/let-7 balance. a Upper graph: Pearson coefﬁcient between RPSAP52 expression
levels and CGI methylation in the TCGA sarcoma cohort indicates a negative correlation. Lower graph: Pearson’s index indicates a weaker association between
RPSAP52 and HMGA2 expression levels in the same cohort. b Upper graphs: RT-qPCR analysis to estimate HMGA2 and RPSAP52 expression levels in a panel of
Ewing’s sarcoma and rhabdomyosarcoma cell lines. Expression is relative to GUSB mRNA levels. Graphs represent the mean ±SD of three independent RNA
extractions. Lower panel: semi-quantitative RT-PCR analysis of expression in the same cell lines. The two RPSAP52 isoforms are indicated, and the higher-
migrating band depicted by an asterisk contains an additional exonic sequence (encompassing coordinates chr12:66,169,917–66,170,002 (hg19)), detected in
those cells lines with the highest expression of RPSAP52. c RNA pull-down assays conﬁrm the interaction of RPSAP52 with IGF2BP2 and HNRNPQ in A673 cell
extracts. Different truncated fragments of RPSAP52 were assayed as indicated, and the band identiﬁed by MS and corresponding to IGF2BP2 and HNRNPQ is
indicated on the protein gel (left). Western blot to test the association between RPSAP52 RNA and IGF2BP2 and HNRNPQ proteins (middle panel). The
drawing summarizes the data obtained from the pull-downs (right). d Total RNA from A673 stable clones constitutively expressing sh1 or sh4 shRNA
sequences was analyzed by RT-qPCR to assess HMGA2 and RPSAP52 transcripts levels (lower graph) or let-7miRNAs levels (upper graph). Graphs represent
the mean ±SD of three independent replicates. e Western blot on A673 clones to analyze protein levels upon stable knockdown of RPSAP52 transcripts.
f Growth-inhibitory effect of RPSAP52 knockdown in A673 mice tumor xenografts. Upper graph: tumor volume (n= 10) was monitored over time. Mean
values are shown ±SEM. Lower graph: tumors were excised and weighed at 25 days. The photograph shows the relative size of all tumors extracted. Scale bar
= 10mm. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11910-6 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3979 | https://doi.org/10.1038/s41467-019-11910-6 | www.nature.com/naturecommunications 9
unexplored. Our previous work had shown that the transcribed
pseudogene RPSAP52 enhances HMGA2 transcription through
the formation of an R loop structure23. We have further explored
the impact of RPSAP52 expression in cell physiology and propose
a mechanism of action that also inﬂuences post-transcriptional
regulation in the cytoplasm through the interaction with the RNA
binding protein IGF2BP2. Regulation of IGF2BP2 expression or
function by lncRNAs appears as a common theme in a number of
lineage commitment programs, including adipocyte, cardiac or
muscle differentiation48–50. However, while other studies have
reported lncRNAs that interact with IGF2BP2 and compete for its
binding to target mRNAs (e.g., LncMyoD promotes muscle dif-
ferentiation by outcompeting c-Myc and N-Ras mRNAs for
IGF2BP2 binding48), in the cancer setting that we are studying
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reexpression of RPSAP52 facilitates IGF2BP2 binding to a subset
of mRNA targets, prominently HMGA2 and LIN28B mRNAs.
Our data indicate that this is achieved through modulation of the
binding afﬁnity that IGF2BP2 has for particular 3′UTRs and its
distribution in large polysomes. This is reminiscent of the
mechanism of action of HIF1A-AS2 in glioblastoma cell lines,
where binding of an antisense transcript to IGF2BP2 and
DHX9 stimulates expression of their target mRNAs and promotes
adaption to hypoxic stress51. Thus, our working model is that by
forming ternary complexes (IGF2BP2-RPSAP52-other mRNAs),
RPSAP52 may inﬂuence the recruitment into ribonucleoprotein
particles that dictate mRNA fate, and in particular enhance the
translation of mRNAs that would otherwise be repressed by
miRNAs. Binding by IGF2BP3 (another member of the IGF2BP
family), for instance, has been associated with resistance to
miRNA-dependent destabilization for many oncogenes, including
HMGA2 and LIN28B52. We hereby describe a similar scenario for
IGF2BP2, and IGF2BPs are thus emerging as key nodes that
integrate lncRNA-mediated post-transcriptional regulation of
gene expression and pro-proliferative and self-renewal axis.
An important added layer of regulation exerted by RPSAP52 is
the inﬂuence on let-7 levels, which may be a consequence of the
control on LIN28B translation efﬁciency, or (in those cells where
LIN28B is absent, such as MCF10A), may derive from the altered
levels observed in IGF2BP2 protein itself upon depletion of the
pseudogene. In fact, in glioblastoma cells lacking LIN28, let-7
targets have been observed to be protected from miRNA-
dependent silencing by the binding of IGF2BP2 to let-7 miRNA
responsive elements27. This in turn may indirectly cause a
decrease of let-7 levels, since miRNA turnover might also depend
on binding to mRNA targets, with some previous evidence sug-
gesting that target availability prevents miRNA decay53,54. The
greater effect of directly inhibiting biogenesis versus indirectly
inﬂuencing the turnover might explain why let-7 levels increase
moderately in MCF10A upon RPSAP52 depletion (where LIN28B
is not expressed and LIN28A is not altered, but IGF2BP2
levels decrease), and, by contrast, increase by almost one order of
magnitude more in A673 cells (where expression of LIN28B
protein is reduced) (compare Figs. 2c and 4d). Taken as a
whole, RPSAP52 is a pseudogene with an important impact on a
major tumor suppressor miRNA. While silencing of HMGA2
expression by let-7 has been reported before55, this is the ﬁrst
time that regulation of let-7 levels by transcripts originating from
HMGA2 locus is proposed. Importantly, this effect does not
proceed through HMGA2 itself, since depletion of HMGA2
expression with gapmers actually increases RPSAP52 levels and
consequently results in a decrease in let-7 family (Fig. 2e). This
adds further complexity to the regulatory network, one hypoth-
esis being that the tumorigenic cell activates an alternative
pathway (increase of RPSAP52) to compensate for the loss of
HMGA2 function.
Consistent with their convergent roles in the same pathway,
low expression of HMGA2/RPSAP52 in differentiated cells and
reexpression in cancer mirrors LIN28 levels, which is one of the
key players in maintenance of the pluripotent state. Let-7 levels
are maintained low in embryonic stem cells and certain primary
tumors due to inhibition by LIN28 proteins, which are present at
characteristically high levels in undifferentiated cells56,57. Of all
tumor suppressor miRNAs, let-7 is the one whose loss is most
frequently correlated with poor prognosis in meta-analysis
reports58. Accordingly, LIN28A/B high expression is a marker
of poor prognosis and more aggressive tumors in a variety of
cancers, and their levels have also been associated with metastatic
and drug-resistant cases59. Thus, regulation of LIN28B/let-7
balance is one important driver in cancer development.
An important aspect of this LIN28B/let-7 balance is their
counteracting action on the stemness characteristics of cancer
cells. Interestingly, LIN28B/let-7 signaling has been shown to
regulate endogenous Oct4 and Sox2 expression by using ARID3B
and HMGA2 as downstream effectors, and thereby regulate
stemness properties in oral squamous cancer60. Also, the role of
let-7 in antagonizing self-renewal and promoting differentiation
has been established via targeting of Myc, Ras, and HMGA2
pathways61,62. In accordance with let-7 anti-pluripotency prop-
erties, we observe a decrease in NANOG and OCT4 levels as well
as in clonogenicity upon RPSAP52 depletion (Fig. 3d, e), sug-
gesting that RPSAP52 is an enhancer of stem cell characteristics.
To date, few lncRNAs have been thoroughly described regarding
their involvement in stemness, among them H19 (whose down-
regulation reduces NANOG, OCT4, and SOX2 in glioma and
breast cancer63) and lncRNA ROR (which inhibits proliferation of
glioma stem cells by negatively regulating KLF464). In particular,
H19 has recently been proposed to facilitate tumorigenesis
through sponging of let-765. The regulatory mechanism used by
RPSAP52, by contrast, targets let-7 family through modulation of
LIN28B and/or target availability.
Taken together, we have observed that RPSAP52 (1) stimu-
lates proliferative and self-renewal axes together with a reduc-
tion of let-7 levels, (2) promotes tumorigenic behavior in vitro
and in vivo, and (3) is overexpressed in a number of human
cancers and its expression is associated with worse outcome.
This, together with its virtual absence in normal differentiated
cells and embryonic expression pattern allows us to propose that
RPSAP52 is an oncofetal pseudogene that enhances proliferative
Fig. 5 Binding of IGF2BP2 to its mRNA targets is affected by RPSAP52 knockdown. a IGF2BP2 was immunoprecipitated from A673 extracts and the pulled-
down RNA was analyzed by RT-PCR. The IGF2BP2 and NRAS mRNAs were used as positive controls. Gel images represent semi-quantitative RT-PCR,
whereas data on graphs represent means of two independent RT-qPCR analysis ±SD. b Immunoprecipitation of IGF2BP2 from A673 extracts followed by
western blot of retrieved proteins. 10% of total extract prior to IP was loaded as control (input). c IGF2BP2 was immunoprecipitated in control or RPSAP52-
depleted A673 cells, and the retrieved proteins and RNAs were isolated and analyzed by western blot (left) or RT-qPCR (right), respectively. Graphs
correspond to means from two replicates ±SD. d Analysis of IGF2BP2 binding targets from iCLIP-seq experiments in control (scr) or depleted cells (sh4
B11). The absolute number of peaks mapping to 3′UTR regions were 1762 (scr) and 622 (sh4), and to intronic regions were 973 (scr) and 846 (sh4).
Asterisks correspond to P-values < 2.2e–16 (two-tailed Fisher’s tests). e Above: heatmap of genes with differential iCLIP counts on their 3′UTR. Results
from two experiments are shown. Below: differential enrichment of these genes according to GO biological process categories (top ten are shown).
f Above: Venn diagram showing the relation between genes with signiﬁcant iCLIP peaks present on their 3′UTR regions in the control (scr) or RPSAP52-
depleted (sh4) sample. Below: top ten GO enrichment categories (Biological process) for the same genes in the scr or sh4 sample. g UCSC Genome
Browser view of LIN28B 3′UTR with the read coverage from IGF2BP2 iCLIP experiment. Previous IGF2BP2-CLIP data positions are shown in red, and
predicted let-7 binding sites are indicated by the arrows. h UCSC Genome Browser view of HMGA2 3′UTR with the read coverage from IGF2BP2 iCLIP
experiment. Position of signiﬁcant peaks and CITS are shown above the proﬁles, and predicted let-7 binding sites are indicated by the arrows. Source data
are provided as a Source Data ﬁle
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and survival programs across several tumor types and whose
expression in cancer can have important clinical implications.
Indeed, RPSAP52 levels are more useful as biomarkers in sar-
coma than HMGA2 mRNA levels, which do not seem to cor-
relate well with protein levels (as suggested by our work and
others66), probably due to the complex post-transcriptional
regulation of HMGA2. The potential use of this pseudogene as
an effective therapeutic target in human cancer will thus be the
focus of future studies.
Methods
DNA methylation analysis. Genome-wide DNA methylation analysis was
performed with the 450K DNA methylation microarray from Illumina
(Inﬁnium HumanMethylation450 BeadChip). Bisulﬁte-treated DNA from the
indicated breast cancer cell lines was hybridized onto the array. A three-step
normalization procedure was performed using the lumi package v2.30.0
(available for Bioconductor, within the R v3.4.3 statistical environment),
consisting of color bias and background level adjustment and quantile normal-
ization across arrays. The methylation level (β-value) of CpG sites was calculated
as the ratio of methylated signal divided by the sum of methylated and unme-
thylated signals.
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Fig. 6 IGF2BP2 is redistributed on polysome gradients upon RPSAP52 depletion. a–d Polysome proﬁles of A673 cells stably depleted of RPSAP52
(shRPSAP52, corresponding to sh4 B11 clone) or control cells (scr). HMGA2 mRNA (a), LIN28B mRNA (b), or NRAS mRNA (c) distribution across the
gradient was evaluated in each fraction by RT-qPCR. For comparison, GAPDHmRNA distribution was also assessed (d). Graphs represent the mean ±SD of
three replicates. The red and blue lines indicate absorbance at 260 nm for each fraction in control or depleted cells, respectively. e Total RNA from the
same cells (n= 3) was analyzed by RT-qPCR. Mean values are shown ±SD. A two-tailed student t-test was used (*P < 0.05, **P < 0.01). f Protein extracted
from the 20% of the polysome proﬁle fractions shown in (a–d) were subjected to dot blot analysis with an anti-IGF2BP2 antibody (middle panel) or with
anti-RPL5 antibody as control (lower panel). Proteins from 10% of fractions 1 and 2 were loaded together. Membranes were previously stained with
Ponceau S (top panel) for loading control. Source data are provided as a Source Data ﬁle
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Bisulﬁte genomic sequencing. The Methyl Primer Express v1.0 software
(Applied Biosystems) was used to design speciﬁc primers for the methylation
analysis of HMGA2/RPSAP52 island (Supplementary Table 1). Genomic DNA
(1 µg) was subjected to sodium bisulﬁte treatment using the EZ DNA
Methylation-Gold kit (Zymo Research). For bisulﬁte genomic sequencing,
300–500 bp fragments were ampliﬁed using 1–2 μl of bisulﬁte-converted DNA
with Immolase Taq polymerase (Bioline) for 42 cycles. The resulting PCR
products were gel-puriﬁed with NucleoSpin® Gel and PCR Clean-up
(Macherey-Nagel) and then cloned into the pSpark® TA vector (Canvas)
according to the manufacturer’s protocol. For all samples, 10 colonies were
randomly chosen, the DNA was puriﬁed using NucleoSpin® 96 Plasmid
(Macherey-Nagel) and sequenced by the 3730 DNA Analyzer (Applied Bio-
systems). After sequencing analysis with BioEdit v7.2.5 software, C nucleotides
that remained unaltered were transformed into percentages of CpGs showing
methylation.
Western blotting. Cell pellets were resuspended in lysis buffer (50mM Tris-HCl pH
8, 5 mM EDTA, 350mM NaCl, 0.5% NP40, 10% glycerol, 0.1% SDS and phosphatase
inhibitors), sonicated and centrifuged to recover the supernatant. The concentration
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was determined with the Pierce BCA Protein Assay Kit (#23227, ThermoFisher).
Proteins were boiled for 5min with Laemmli buffer (2% SDS, 10% glycerol, 60 mM
Tris-Cl pH 6.8, 0.01% bromophenol blue) plus 2% 2-mercaptoethanol as a loading
buffer, and equal amounts of extracts were loaded onto Tris-Glycine-SDS gels. Pro-
teins were transferred to a nitrocellulose membrane (Whatman, GE Healthcare) and
incubated overnight at 4 °C with primary antibodies diluted in 5% skimmed milk in
PBS containing 0.1% Tween-20. The detected proteins were IGF2BP2 (H00010644-
M01, Abnova, 1:500), RAS (ab55391, Abcam, 1:500, which recognizes all RAS pro-
teins), LIN28B (ab71415, Abcam, 1:1000), IGF1R (#3027, Cell Signaling, 1:1000), ERK
(#4695, Cell Signaling, 1:1000), p-ERK (#9101, Cell Signaling, 1:1000), LAMIN B1
(ab16048, Abcam, 1:4000), LIN28A (#8641, Cell Signaling, 1:750), α-TUBULIN HRP
(ab40742, Abcam, 1:5000), HNRNPQ (ab184946, Abcam, 1:10,000), β-ACTIN HRP
(a3854, Sigma, 1:20,000), NANOG (#4903, Cell Signaling, 1:2000), OCT4 (#2750, Cell
Signaling, 1:1000), SOX2 (#4195, Cell Signaling, 1:1000), NUCLEOLIN (#8031, Santa
Cruz, 1:2000), HMGA2 (ab97276, Abcam, 1:1000), HISTONE H3 (ab1791, Abcam,
1:5000), RPSA (ab133645, Abcam, 1:1000), and RPL5 (A303-933A, Company Bethyl,
1:1000). After three washes with PBS containing 0.1% Tween-20, membranes were
incubated for 1 h at room temperature in a bench-top shaker with the secondary
antibodies conjugated to horseradish peroxidase anti-rabbit IgG (A0545, Sigma,
1:10,000) or anti-mouse IgG (NA9310, GE HealthCare, 1:5000). ECL reagents
(Luminata-HRP; Merck-Milllipore) were used to visualize the proteins.
Nuclear/cytoplasmic fractionation and poly(A) selection. Subcellular fractio-
nation was performed with PARIS™ kit (#AM1921, Life Technologies). Equal
amounts of RNA from each fraction were subject to RT-qPCR and the results were
normalized taking into account the total quantity of RNA recovered from each
fraction. To verify the nuclear and cytoplasmic fractionation of the mRNA, RNU6B
and GAPDH were used as controls, respectively. The separation was conﬁrmed at
the protein level by western blot with HISTONE H3 (ab1791, Abcam, 1:5000) and
α-TUBULIN HRP (ab40742, Abcam, 1:5000). Poly(A)+ and poly(A)− RNAs were
separated using the Dynabeads® mRNA Puriﬁcation kit (#61006, Life Technolo-
gies), using three rounds of selection. RNA enrichment in each fraction was then
analyzed by RT-qPCR, using GAPDH and RNU6B as controls.
RNA-biotin pull-down. Full-length RPSAP52 (including alternative exon) or
truncated fragments, as well as the antisense version or the sequence corresponding
to the unrelated Uc.160+ RNA, were biotin-labeled by standard in vitro tran-
scription reactions and gel-puriﬁed. DNA templates for transcription were pre-
pared by PCR with oligos described in Supplementary Table 1. The pull-downs
were carried out with 10 pmol of each biotinylated RNA and 1mg of total MCF10A
or A673 protein extracts. Following incubation with the extract, each RNA was
retrieved with 25 μl of Dynabeads® M-270 Streptavidin beads (#65305, Invitrogen)
and washed in RIP buffer (150 mM KCl, 25 mM Hepes at pH 7.9, 5 mM EDTA,
0.5 mM DTT, 0.5% NP40, 1 × protease inhibitor cocktail (Roche)). Binding pro-
teins were released through boiling in SDS loading buffer and samples were run on
a 4–12% gradient pre-cast Bis-Tris protein gels (Invitrogen) in MOPS buffer. After
electrophoresis, the gels were either stained with SYPRO Ruby (Invitrogen) for
band visualization and MS analysis or transferred to nitrocellulose membranes for
western blotting.
In-gel digestion and LC-MS/MS analysis. Gel bands were manually excised and
digested with trypsin overnight. Bands were then washed with water, 50 mM
ammonium bicarbonate and 50% acetonitrile. Samples were subsequently reduced
with 10 mM DTT and alkylated with 35 mM iodoacetamide. Extracted peptides
were analyzed on a Ion Trap Amazon Speed ETD (Bruker Daltonics, Bremen,
Germany) ﬁtted with a captivespray source (Bruker, Daltonisc) following separa-
tion with Easy-nLCII apparatus (Proxeon). Peptides were separated in a reverse
phase chromatography using a nano-capillary analytical c18 column. Peptide
masses were analyzed at full scan MS, and then at MS/MS fragmentation for the
most intense peaks. Data were analyzed using the Mascot search engine and the
SwissProt human database.
Reverse pull-down. Endogenous IGF2BP2 was immunoprecipitated from A673
cell extracts. One milligram of total protein was incubated overnight with 2 μg of
anti-IGF2BP2 polyclonal antibody (#H00010644-M01, Abnova) or control mouse
IgG antibody (#12-371, Millipore) and 40 μl of Dynabeads® M-280 anti-mouse IgG
beads (#11202D, ThermoFisher) in 1 ml of RIP buffer (150 mM KCl, 25 mM Hepes
at pH 7.9, 5 mM EDTA, 0.5 mM DTT, 0.5% NP40, 1× protease inhibitor cocktail
(Roche)). Beads were then washed three times with RIP buffer and 10% of the
volume was boiled in the presence of Laemmli buffer for western blot analysis. The
pulled-down RNA in the remaining 90% of beads was extracted by adding 1 ml of
TRIzol® Reagent (15596-018, ThermoFisher). After phenol extraction and iso-
propanol precipitation, the ﬁnal pellet was resuspended in 10 µl of H2O and ret-
rotranscribed. cDNA was analyzed by either 30 cycles of semi-quantitative RT-PCR
or by RT-qPCR (Applied Biosystems 7900HT Fast Real-Time PCR System). Two
micrograms of input RNA was processed in parallel to estimate pull-down
efﬁciency.
Cell culture. MCF7, MCF10A, HCC1143, and A673 cell lines were purchased from
ATCC. The remaining breast and sarcoma cell lines were obtained from Dr.
Esteller and Dr. Tirado’s labs, respectively. Authenticity of the cell lines was rou-
tinely conﬁrmed by STR proﬁling analysis done at qGenomics SL (Esplugues de
Llobregat, Barcelona, Spain). All cell lines were routinely checked for mycoplasma
contamination. Non-malignant MCF10A breast cells were grown in DMEM/Ham’s
F-12 medium (#L0093-500, Biowest) supplemented with 20 ng ml−1 EGF
(#SRP3027, Sigma), 500 ng ml−1 hydrocortisone (#H0888, Sigma), and 10 µg ml−1
insulin (#I9278, Sigma). Ewing’s sarcoma A673 cells and breast cancer HCC1143
cell line were grown in RPMI-1640 medium with GlutaMAX (#61870-010, Gibco).
HEK293T cells, used for the production of lentiviral particles, and breast cancer
Hs578T cell line were cultivated in DMEM with GlutaMAX (#31966-021, Gibco).
All the media were supplemented with 10% fetal bovine serum (FBS) (#10270,
Gibco), and the cells were grown at 37 °C in a humidiﬁed atmosphere of 5% CO2
and 95% air.
Plasmid construction and transfections. Stable knockdown of RPSAP52 was
achieved with the following sequences: shRNA1 and shRNA4 target, respectively,
the 5′TCCTTAAGCTCCTTGCAGT3′ and 5′CACGGACTCTTAAGCAACA3′
sequences of RPSAP52 mRNA (both located on the last exon), whereas shRNA3
targets the 5′GTGCAAGACTCAGGAGCTA3′ sequence of RPSAP52 (on the ﬁrst
intron, which is inefﬁciently spliced). These shRNAs were expressed by cloning
oligos shRPSAP52-1for and shRPSAP52-1rev (shRNA1), shRPSAP52-4for and
shRPSAP52-4rev (shRNA4), and shRPSAP52-3for and shRPSAP52-3rev
(shRNA3) into the BamHI and EcoRI sites of the vector pLVX-shRNA2 (Clon-
tech). A scramble (scr) sequence was used as a control. For lentivirus-mediated
depletion, HEK293T cells were transfected with pLVX-shRNA2-constructs plus
packaging plasmids with jetPRIME® (Polyplus-transfection) according to the
manufacturer’s recommendations. The target cell line was infected with the
supernatant containing viral particles 48 h post-transfection. ZsGreen1 was used as
a marker to visualize transductants by ﬂuorescence microscopy, and these cells
were selected by ﬂuorescence-activated cell sorting (FACS) and plated to obtain
stable clones. Antisense oligonucleotides (LNA™ GapmeRs, #300600, Exiqon) tar-
geting HMGA2 mRNA (HMGA2), exon1 (RPSAP52 Ex) or the ﬁrst intron
(RPSAP52 RL1 and RL2) of RPSAP52 transcript were transfected to a ﬁnal con-
centration of 65 nM using HiPerfect (Qiagen). Cells were retransfected 48 h later
and collected 72 h after the second round of LNA treatment. A control LNA
GapmeR (#300610, Exiqon) was used as mock transfection. For siRNA-mediated
knockdown of LIN28B, cells were transfected with a 1:1 mix of two different
siRNAs against LIN28B (#216387-216388, Ambion) and a negative control (C-)
(#AM4611, Ambion), using LipofectamineTM RNAiMAX Transfection Reagent
Fig. 7 RPSAP52 expression inﬂuences proliferative cellular programs and is a prognosis factor. a Left: Volcano plot indicating differential expression (green
= down, red= up) between control (scr) and RPSAP52-depleted (sh4) A673 cells. The vertical green lines correspond to 2.0-fold up and down,
respectively, and the horizontal green line represents a P-value of 0.05 (two-tailed unpaired t-test). Right: enriched GO terms for shRNA-RPSAP52-affected
genes. The y axis shows GO terms and the x axis shows statistical signiﬁcance (two-tailed Fisher’s exact test). b RT-qPCR analysis of candidate genes
altered in RPSAP52-depleted A673 cells. Clones stably expressing two different shRNAs were analyzed. Graphs represent the mean ±SD of three replicates
(two-tailed unpaired student t-test, ***P < 0.001, ****P < 0.0001). c Above: in the TCGA sarcoma cohort, Kaplan–Meier analysis of overall survival indicates
that patients with high RPSAP52 expression levels have poorer prognosis than cases with low expression. Below: HMGA2 expression has no prognostic
value in the same cohort. Signiﬁcance of the log-rank test is shown. d Kaplan–Meier analysis of overall survival in the sarcoma cohort from TCGA,
indicating that patients with a hypermethylated HMGA2/RPSAP52 promoter display better prognosis. e Summary of the results in the context of HMGA2/
IGF2BP2/let-7 axis. RPSAP52 positively regulates HMGA2 expression through both transcriptional and post-transcriptional mechanisms. Binding of
RPSAP52 to IGF2BP2 in the cytoplasm might promote downregulation of let-7 levels by LIN28B-dependent and independent mechanisms. This binding
could also modulate the formation of mRNPs for a number of IGF2BP2 mRNA targets, thereby directing their translation efﬁciency. Source data are
provided as a Source Data ﬁle
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11910-6
14 NATURE COMMUNICATIONS |         (2019) 10:3979 | https://doi.org/10.1038/s41467-019-11910-6 | www.nature.com/naturecommunications
(#13778, Invitrogen) according to the manufacturer’s recommendations. The
overexpression of LIN28B was achieved with pcDNA3-FLAG-Lin28B (#51373,
Addgene), and we used pcDNA3.1+ (Invitrogen) as a control (empty) and jet-
PRIME® (Polyplus-transfection) as the transfection reagent.
Transcription/translation assay. RPSAP52 full-length transcript (from RefSeq
NR_026825 annotation) was ampliﬁed by PCR from A673 cDNA with oligos T7-
RPSAP52for-TnT and RPSAP52rev-TnT, producing two isoforms that include or
exclude the alternative exon downstream of the T7 bacteriophage promoter. After
gel puriﬁcation, the PCR product was used directly in coupled transcription and
translation reactions in reticulocyte extracts (TNT® Quick Coupled Transcription/
Translation Systems, Promega), following the manufacturer’s indications and by
labeling the reactions with 35S. The translation products were separated by SDS-
PAGE, the gel was then vacuum-dried and exposed overnight with an
autoradiography ﬁlm.
RNA isolation and RT-qPCR analysis. Total RNA, including miRNAs, was
extracted using the Maxwell® RSC instrument with the Maxwell® RSC miRNA
Tissue kit (Promega) according to the manufacturer’s recommendations. For
mRNA expression analysis, total RNA was reverse transcribed using the Super-
ScriptTM III Reverse Transcriptase (#18080, Invitrogen). Real-time PCR reactions
were performed in triplicate in an Applied Biosystems 7900HT Fast Real-Time
PCR system, using 30–100 ng cDNA, 6 µl SYBR® Green PCR Master Mix (Applied
Biosystems), and 416 nM primers in a ﬁnal volume of 12 µl for 384-well plates. All
data were acquired and analyzed with the QuantStudio Design & Analysis Software
v1.3.1 and normalized with respect to GUSB as endogenous control. Relative RNA
levels were calculated using the comparative Ct method (ΔΔCt). For miRNA
expression analysis, miRCURY LNA™ Universal RT microRNA PCR System
(Exiqon) was used, according to the manufacturer’s recommendations, with the
Universal cDNA Synthesis Kit II (#203301) for the RNA retrotranscription and the
ExiLENT SYBR® Green master mix (#203421) for the RT-qPCR in the Light-
Cycler® 480 (Roche) with the LightCycler® 480 Software v1.5.0 SP4. To normalize
the data, RNU6B or miR-195 were used as endogenous control.
Actinomycin D treatment and RNA stability analysis. Control or RPSAP52-
depleted A673 clones were treated with either 0.5% DMSO or 5 µg ml−1 Actino-
mycin D (Sigma) for 9 h. Pellets of each condition and treatment were harvested at
different times and RNA was extracted for the RT-qPCR experiments. All data
were normalized with respect to GUSB as endogenous control and gene expression
fold-changes induced by Actinomycin D were calculated relative to the control
(DMSO) cells of each condition and time point. c-FOS and GAPDH were used as
controls of the experiment due to their short and long half-life, respectively.
SRB assay. Cell viability and proliferation were determined by the sulforhodamine
B (SRB) assay. Cells were seeded in 96-well microplates in medium with 10% FBS,
and the experiment started after 24 h of incubation at 37 °C and 5% CO2. The
optimal cell number (100 cells per well for MCF10A and 2000 cells per well for
Hs578T and HCC1143) was determined to ensure that the cells were in growth
phase at the end of the assay. During 7 consecutive days, at least 6 wells per
condition were processed as follows. The medium was removed and the cells were
ﬁxed with 10% trichloroacetic acid for 1 h at 4 °C. Then, two washes with 1% acetic
acid were performed and the viable cells were stained with 0.057% SRB in 1% acetic
acid. Following 30 min of incubation at RT, the SRB was removed by washing twice
with 1% acetic acid. The wells were air-dried completely and the SRB bound to the
viable cells was dissolved with 100 μl of Tris-HCl 10 mM (pH 10.0). Absorbance at
540 nm was determined on an automatized microtiter plate reader PowerWave XS
(BioTek).
Colony formation assay. Cells were seeded into 35 mm dishes with three tripli-
cates per condition at a density of 200 cells per plate for MCF10A and HCC1143
and 500 cells per plate for Hs578T. They were maintained for 8–15 days in a
humidiﬁed incubator with 5% CO2 at 37 °C. Cells were then ﬁxed in 4% paraf-
ormaldehyde and stained with 0.5% crystal violet for 30 min. Digital images were
obtained using GBox (Syngene) and colonies containing more than 50 cells were
counted manually using ImageJ v1.50 software. Plating efﬁciency and survival
fractions were determined by using the following formulas:
Plating efficiency ¼ number of colonies obtained
number of cells seeded
Surviving fraction ¼ plating efficiencynumber of colonies obtained in the control condition ´ 100
Real-time migration assay. The xCELLigence Real-Time system (ACEA Bios-
ciences) was used with CIM-16 plates of 8 μm pore membranes. The lower
chamber wells were ﬁlled with 160 μl of medium containing 10% FBS and the top
chamber wells with 40 μl of serum-free medium. The two chambers were assem-
bled together and allowed to equilibrate for 1 h at 37 °C and 5% CO2. Cells were
incubated for 24 h in serum-free medium, rinsed with PBS, trypsinized and
resuspended in medium supplemented with 10% FBS to inactivate the trypsin,
followed by centrifugation and resuspension in serum-free medium. A total of 8 ×
104 cells were seeded onto the top chamber of CIM-16 plates and placed into the
xCELLigence system for data collection after background measurement. The
software RTCA 2.0 was set to collect impedance data every 15 min. The cell index
represents the capacity for cell migration, whereas the slope of the curve can be
related to the cell invasion ability.
Transwell migration assay. Transwell® Permeable Supports (#3422, Cultek) with
8 μm pore polycarbonate membranes in 24-well plates were used to measure cell
migration. Cells were incubated for 24 h in serum-free medium, rinsed with PBS,
trypsinized, and resuspended in 10% FBS-containing medium to inactivate the
trypsin, followed by centrifugation and resuspension in serum-free medium. A
total of 1 × 105 cells were seeded onto each transwell with 150 μl of serum-free
medium and the transwells were placed in the wells of a 24-well plate with 500 μl of
10% FBS-containing medium. The chemoattractant promoted the migration of the
cells from the upper part of the transwell to the lower part. After 24 h of incubation
at 37 °C and 5% CO2, the cells in the upper part of the membrane were removed
with a cotton swab and several washes with 1× PBS. Cells in the lower part were
ﬁxed for 10 min with ice-cold 100% methanol. For the staining, cells were covered
with 0.5% crystal violet in 25% methanol for 10 min. Transwells were washed
several times with 1× PBS and air-dried. Membranes were then mounted on a slide
for image acquisition.
Clonogenicity assay. The clonogenicity of RPSAP52-depleted MCF10A clones was
tested in soft agar by using the CytoSelect 96-well Cell Transformation Assay Kit
(Cell Biolabs, #CBA-130), following the manufacturer’s instructions. Brieﬂy, a base
agar layer was prepared by mixing equal volumes of 1.2% agar solution and 2×
DMEM/20%FBS medium in each well of a 96-well ﬂat-bottom microplate. In total,
5000 cells per well were seeded in a top layer by mixing equal volumes of the cell
suspension, 1.2% agar solution and 2× DMEM/20%FBS (1:1:1), and incubated for
6 days after covering the solidiﬁed cell agar layer with 100 µl of DMEM-F12
medium plus supplements. The CyQuant GR dye was used to detect the lysed
colonies and the proportional ﬂuorescence to the number and size of colonies was
read using a PerkinElmer’s VICTOR X5 multilabel plate reader with a 485/535
ﬁlter set and 1 s of measurement time. The data are expressed in relative ﬂuores-
cence units (RFU).
In vivo xenograft. Athymic nude female mice (Charles River, Inc (USA), strain
Crl:NU(NCr)-Fox1nu) were subcutaneously injected at 7–8 weeks of age in one
ﬂank with a total of 10 × 106 MCF10A, 7 × 106 A673, and 5 × 105 Hs578T cells
from clones expressing either scrambled or RPSAP52-shRNAs, soaked in 100 µl of
Matrigel (BD Biosciences). Tumor growth was monitored every 7 days for
MCF10A, 3–4 days for A673, and 4 days for Hs578T by measuring tumor width
(W, mm) and length (L, mm) until mice were killed at the indicated days post-
injection. After allowing to grow for several weeks, tumor volume (V, mm3) was
estimated from the formula V ¼ π ´ L ´W26 and tumor weight (g) measured. Animal
tests complied with ethical regulations. All the mouse experiments were approved
by IDIBELL’s Committee for Animal Experimentation.
Absolute quantiﬁcation. Estimations of the absolute amounts of RNAs were
obtained by comparison with in vitro transcribed RNA standards of known con-
centration. These RNA standards correspond to the sequences ampliﬁed in RT-
qPCR in the analysis of RPSAP52+ altex, RPSAP52 – altex, HMGA2 and LIN28B
transcript expression in all ﬁgures, and were generated by introducing the T7 RNA
Polymerase promoter upstream of the amplicon by PCR and subsequent in vitro
transcription. Serial dilutions of the synthesized RNA standards were used as spike-
ins in total RNA extractions from MCF7 cells (which do not express any of the
transcripts of interest) and processed in parallel in RT-qPCR with RNA extractions
from a known number of MCF10A or A673 cells, so that transcript copy number
per cell could be measured. Similarly, for determination of let-7 copy number, we
generated a standard curve using synthetic let-7a, b and e puriﬁed RNA oligonu-
cleotides (Sigma), corresponding to the sequences hsa-let-7a-5p (5′-rUrGrArGr-
GrUrArGrUrArGrGrUrUrGrUrArUrArGrUrU-3′), hsa-let-7b-5p (5′-r
UrGrArGrGrUrArGrUrArGrUrUrGrUrGrUrGrGrUrU-3′), and hsa-let-7e-5p (5′-
rUrGrArGrGrUrArGrGrArGrGrUrUrGrUrArUrArGrUrU-3′). For protein quan-
tiﬁcation, total extracts from a recorded number of cells was analyzed by western
blot in parallel with known amounts of the following recombinant proteins:
LIN28B (ab134596, Abcam), IGF2BP2 (ab153107, Abcam), HNRNPQ (ab153089,
Abcam). Western blot was performed with the following antibodies: anti-LIN28B
(ab71415, Abcam, 1:1000), anti-IGF2BP2 (H00010644-M01, Abnova, 1:500), anti-
HNRNPQ (NBP1-57197, Novus Biologicals, 1:1000). Band intensity was measured
by densitometry with an iBright™ CL1000 Imaging System (ThermoFisher).
iCLIP-seq. iCLIP-seq was performed on stable A673 clones. Approximately 8 × 106
A673 cells stably expressing scrambled shRNA (scr) or shRNA-4 against RPSAP52
(clone B11) were crosslinked with 150 mJ cm−2 total 254-nm irradiation in a
Stratalinker 2400. The same amount of non-crosslinked cells were used as controls.
Cell lysates were treated with different concentrations (2 or 0.4 U µl−1) of RNaseI
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(#AM2294, ThermoFisher) and 4 U of Turbo DNase (#AM2238, ThermoFisher) in
a ﬁnal volume of 1 ml. Lysates were then cleared and immunoprecipitated over-
night at 4 °C with 10 µg of anti-IGF2BP2 antibody (#RN008P, MBL) preincubated
for 1 h at room temperature with 60 µl anti-rabbit IgG Dynabeads (#11204D,
ThermoFisher). After two washes in high-salt buffer (50 mM Tris-HCl pH 4.4, 1 M
NaCl, 1 mM EDTA, 1% Igepal CA-630, 01% SDS, 0.5% sodium deoxycholate) and
one wash in PNK buffer (20 mM Tris-HCl pH 7.4, 10 mMMgCl2, 0.2% Tween-20),
RNA 3′end was dephosphorylated with PNK for 20 min at 37 °C. Beads were then
washed once with PNK buffer, once with high-salt buffer and twice with PNK
buffer. L3 adapter was then ligated overnight at 16 °C in a 20 µl reaction containing
1.5 µM pre-adenylated L3-App adapter (rAppAGATCGGAAGAGCGGTTCAG//
ddC/), 4 µl PEG400 and 10 U T4 RNA Ligase1 (#M0204, New England Biolabs).
Beads were then washed twice with high-salt buffer and twice with PNK buffer, and
20% of beads were radioactively labeled with γ-[32P]-ATP and 0.5 U µl−1 PNK
(#M0201, New England Biolabs) for 5 min at 37 °C, added to the remaining cold
beads and incubated in 20 µl 1xNuPAGE buffer for 5 min at 70 °C prior to loading
the supernatant on a 4–12% NuPAGE Bis-Tris gel (#NP0341BOX, ThermoFisher).
The gel was run at 180 V for 50 min, and the protein–RNA complexes were
transferred to a nitrocellulose membrane at 30 V for 1 h. The membrane was then
autoradiographed through exposure to a ﬁlm at −80 °C for 1 h. Regions of interest
containing the IGF2BP2-RNA crosslinked products were cut out of the membrane
and the RNA fragments isolated, reverse transcribed, puriﬁed and circularized by
incubating with CircLigase II (Epicentre) for 1 h at 60 °C, followed by annealing to
Cut_oligo (5′-GTTCAGGATCCACGACGCTCTTCAAAA-3′) and digestion with
BamHI. iCLIP libraries were ampliﬁed for 27 cycles with P3/P5 Solexa primers, and
the appropriate size of products were conﬁrmed by gel electrophoresis. Sequencing
of the libraries was performed on a MiSeq instrument following standard manu-
facturer’s procedures, using MiSeq Reagent Kit v3 reagents with single-read, 151-
bases read proﬁle. Two independent experiments were performed for each con-
dition. The four libraries were sequenced in two separated pools (#31 & #38) and
data acquired with MiSeq Reporter v2.6.3.2. Raw data can be downloaded from
https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA484688.
iCLIP computational analysis. Read quality was assessed using FastQC (v0.11.7)
software (available online at http://www.bioinformatics.babraham.ac.uk/projects/
fastqc). After sequencing, PhiX sequences were removed using BWA (Burrows-
Wheeler Aligner, v0.7.17)67. All the pre-processing steps, peak calling, CITS calling,
and annotations were performed using CTK (CLIP Tool Kit) (v1.0.9) software68,
following the recommendations found in https://zhanglab.c2b2.columbia.edu/
index.php/ICLIP_data_analysis_using_CTK. After pre-processing steps, ﬁnal tags
from the two biological replicates of the same condition were merged to proceed
with peak and CITS calling steps. Peak calling was statistically assessed using a
Bonferroni adjusted P-value < 0.05 as a signiﬁcance threshold. For CITS calling, all
tags presenting substitutions were excluded from the analysis, since the abnormally
high frequency of substitutions observed could be due to reverse transcriptase read-
through. CITS were considered signiﬁcant with a P-value < 0.001. No proximity
clustering was applied in either of the analysis. Adapter trimming, sequence
alignments, and alignment manipulations were performed using Cutadapt (v1.16),
BWA and samtools (v1.8), respectively. All genome alignments and annotations
used hg19 human genome (GCA_000001405.1) as a reference. De novo motif
discovery from CITS was performed using HOMER (v4.10) software69, for which a
window of CITS +/−10 nucleotides was taken. Additional python scripts were
used for speciﬁc CAUH motif enrichment analysis. Genome Browser images were
generated using Golden Helix GenomeBrowse® v3.0.0 software (available from
http://www.goldenhelix.com). Let-7a/b/e predicted target genes, used for let-7
enrichment analysis in the obtained peaks, were downloaded from miRDB (http://
www.mirdb.org/). For differential binding analysis, 3′UTR tags obtained after pre-
processing steps by CTK software were used to generate 3′UTR tag counts for each
biological replicate of the two conditions. Using these counts, differential binding
analysis was performed using DESeq2 bioconductor package v1.18.170. Gene
enrichment analyses from signiﬁcant peaks were conducted using Enrichr
v2.0 software (http://amp.pharm.mssm.edu/Enrichr/)71,72. Additional graphics and
statistical analysis were performed using R v3.4.3 programming language (https://
www.R-project.org/).
Primary tumors expression and methylation analysis. RNA expression and
DNA methylation data from different tumor types was collected from The Cancer
Genome Atlas (TCGA) Data Portal (https://tcga-data.nci.nih.gov/tcga). TCGA data
were downloaded using TCGAbiolinks v2.9.273. Bioconductor package from the
current GDC (Genomic Data Commons) harmonized database aligned against
hg38 genome. Box plots analysis represent normalized expression and methylation
values corresponding to TCGA COAD, LUSC, LUAD, THCA, and BRCA projects
from the GDC data portal (https://portal.gdc.cancer.gov/). We use the Wilcoxon
signed-rank test to compare differences between groups. The association between
HMGA2 and RPSAP52 expression in primary tumors and cell lines was estimated
with a Pearson’s correlation. All the statistical analysis and graphical representa-
tions were performed using R v3.4.3. For primary samples, an average of HMGA2/
RPSAP52 promoter methylation >0.26 (median of the population) was considered
as hypermethylated. NCI60 cell lines expression data were downloaded from
cBioPortal database (http://www.cbioportal.org/).
Polysome proﬁle analysis. MCF10A cells or A673 stable clones were plated in
150 mm dishes and treated with 100 µg ml−1 cycloheximide (CHX) at 37 °C for
5 min. Cells were washed twice with cold PBS supplemented with CHX, pelleted
and resuspended in 250 µl of hypotonic lysis buffer (1.5 mM KCl, 2.5 mM MgCl2,
5 mM Tris-HCl pH 7.4, 1 mM DTT, 1% sodium deoxycholate, 1% Triton X-100,
100 µg ml−1 CHX) supplemented with mammalian protease inhibitors (SIGMA)
and RNase inhibitor (NEB) at a concentration of 100 Uml−1, and left on ice for 5
min. Cell lysates were cleared of debris and nuclei by centrifugation for 5 min at
17,000 × g. Protein concentrations were determined by BCA assay and 500 µg of
lysate were loaded on 10–50% sucrose linear gradients containing 80 mM NaCl,
5 mM MgCl2, 20 mM Tris-HCl pH 7.4, 1 mM DTT, 10 Uml−1 RNase inhibitor
with a BIOCOMP gradient master. Gradients were centrifuged on a SW40 rotor for
3.5 h at 217,290 × g. Gradients were analyzed on a BIOCOMP gradient station and
collected in 11 (MCF10A) or 13 (A673) fractions ranging from light to heavy
sucrose. Fractions were supplemented with SDS at a ﬁnal concentration of 1% and
placed for 10 min at 65 °C. To each fraction was added 1 ng of ﬁreﬂy luciferase
mRNA, followed by phenol–chloroform extraction and precipitation with iso-
propanol. Puriﬁed RNAs from each fraction were retrotranscribed and subjected to
qPCR. mRNA quantiﬁcation was normalized to ﬁreﬂy mRNA.
IGF2BP2 coimmunoprecipitation and mass spectrometry analysis. Immuno-
precipitation and sample digestion for mass spectrometry analysis: 1 mg of pre-
cleared protein extract from three replicates of control cells (scr) and cells depleted
for RPSAP52 (sh4 B11 clone) were immunoprecipitated overnight at 4 °C using
5 µg of anti-IGF2BP2 antibody (#H00010644-M01, Abnova) and 40 µl of Dyna-
beads® M-280 anti-mouse IgG beads (#11202D, ThermoFisher) in 1 ml RIP buffer
(150 mM KCl, 25 mM Hepes at pH 7.9, 5 mM EDTA, 0.5 mM DTT, 0.5% NP40, 1×
protease inhibitor cocktail (Roche)). After three washes with RIP buffer, the
resulting material was in-bead digested with trypsin. Brieﬂy, the beads were washed
three times with 500 ml of 200 mM Ammonium Bicarbonate (ABC) and resus-
pended in 60 ml of 6 M Urea 200 mM−1 ABC. The samples were then reduced with
10 ml of 10 mM DTT (1 h, 30 °C) and alkylated with 10 ml of 20 mM Iodoaceta-
mide (30 min, room temperature and darkness). After that, the samples were
diluted with 280 ml of 200 mM ABC and digested with 5 ml of 0.2 mg ml−1
Trypsin for 16 h at 37 °C. The beads were ﬁnally pulled down (5 min at 5000 g), the
supernatant transferred to new, cleaned tubes and acidiﬁed with 20 ml of 100%
Formic acid. The resulting peptides mixtures were desalted using C18 stage tips
(UltraMicroSpin Column, The Nest Group, Inc., MA) and dried in a SpeedVac.
Mass spectrometry analysis (LC-MS/MS): the dried-down peptide mixtures
were analyzed in a nanoAcquity liquid chromatographer (Waters) coupled to a
LTQ-OrbitrapVelos (ThermoScientiﬁc) mass spectrometer. The tryptic digests
were resuspended in 10 μl 1% FA solution and an aliquot of 3 μl of each sample was
injected for chromatographic separation. Peptides were trapped on a Symmetry
C18TM trap column (5 μm, 180 μm× 20mm; Waters), and were separated using a
C18 reverse phase capillary column (ACQUITY UPLC BEH column; 130 Å,
1.7 μm, 75 μm× 250 mm, Waters). Eluted peptides were subjected to electrospray
ionization in an emitter needle (PicoTipTM, New Objective) with an applied
voltage of 2000 V. Peptide masses (300–1700m/z) were analyzed in data dependent
mode, where a full scan MS was acquired in the Orbitrap with a resolution of
60,000 FWHM at 400m/z. Up to the 15th most abundant peptides (minimum
intensity of 500 counts) were selected from each MS scan and then fragmented in
the linear ion trap using CID (38% normalized collision energy) with helium as the
collision gas. The scan time settings were Full MS: 250 ms (1 microscan) and MSn:
120 ms. Generated .raw data ﬁles were collected with ThermoXcalibur (v2.2).
Data analysis: the .raw ﬁles were analyzed with the MaxQuant(v.1.6.2.6a)
software using the built-in search engine Andromeda to search against the
Swissprot Human database downloaded from UniprotKB website in March 26,
2018. The search parameters were set as follow: the enzyme was trypsin with a
maximum of two allowed missed cleavages. Oxidation in methionines as well as
Acetylation at protein N-terminal was set as variable modiﬁcations while
carbamidomethylation in cysteines was set as ﬁxed modiﬁcation. The mass
tolerances for the ﬁrst and main search were set at 20 and 4.5 ppm, respectively. In
addition, only peptides with more than 6 and up to 25 aminoacids were considered.
The ﬁnal list of identiﬁed peptides and proteins were ﬁltered by using a 5% false
discovery rate (FDR) both at peptide and protein level. To enhance the
identiﬁcation of proteins the match between runs option was selected.
Protein–protein interaction analysis: the statistical analysis of the
protein–protein interactions found in our experimental conditions was performed
with the help of the Signiﬁcance Analysis of the INTeractome (SAINT) algorithm
which was implemented in the http://statsms.crg.es/ site.
Expression arrays. Total RNA from each sample was quantiﬁed using the
NanoDrop ND-1000 and RNA integrity was assessed by standard denaturing
agarose gel electrophoresis. For microarray analysis, Agilent Array platform was
employed. The sample preparation and microarray hybridization were performed
based on the manufacturer’s standard protocols. Brieﬂy, total RNA from each
sample was ampliﬁed and transcribed into ﬂuorescent cRNA with using the
manufacturer’s Agilent’s Quick Amp Labeling protocol (version 5.7, Agilent
Technologies). The labeled cRNAs were hybridized onto the Whole Human
Genome Oligo Microarray (4 × 44 K, Agilent Technologies). After having washed
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the slides, the arrays were scanned by the Agilent Scanner G2505C. Agilent Feature
Extraction software (version 11.0.1.1) was used to analyze acquired array images.
Quantile normalization and subsequent data processing were performed using the
GeneSpring GX v12.1 software (Agilent Technologies). Differentially expressed
genes were identiﬁed through Fold Change ﬁltering and Volcano ﬁltering. Pathway
analysis and GO Analysis were applied to determine the roles of these differentially
expressed genes.
Statistical analysis. Bar graphics and statistical comparisons were obtained with
the GraphPad Prism 8.1.2 software. Comparative analyses between different
experimental groups were performed using t-student test and one-way ANOVA
with Bonferroni’s or Dunnet’s post hoc tests for intergroup comparisons. For
cancer patients’ samples, we used the Kaplan–Meier method for survival analysis
and the log-rank test was used to analyze the differences between the groups. Cox
regression method was used to analyze the independent prognostic importance of
expression or methylation. Results of the univariate Cox regression analysis are
represented by the hazards ratio (HR) and 95% conﬁdence interval (CI). Results
were considered signiﬁcant if the P-value was <0.05 (*), <0.01 (**), <0.001 (***), or
<0.0001 (****). Unless otherwise stated, data are presented as the mean ±SD.
Unprocessed scans. All unprocessed and uncropped scans and images can be
found in the source data ﬁle.
Data availability
All relevant data are available from the authors. Raw data for the iCLIP-seq experiment
have been deposited under the accession code PRJNA484688 (https://www.ncbi.nlm.nih.
gov/sra/?term=PRJNA484688). iCLIP-seq peaks and CITS are provided in the Oliveira-
Mateos et al_Supplementary Data 1. The list of signiﬁcant altered transcripts from the
microarray expression analysis is provided in the Oliveira-Mateos et al_Supplementary
Data 2. Numerical source data for Figs. 1e–g, 2c, e, 3a–c, e–g, 4b, d, f, 5a, c, 6a–e, 7b;
Supplementary Figs. 1c, 2b–e, 3c, d, f–h, d–f, 5g, j, 6a, c and 7b and all unprocessed
images and scans for Figs. 1d, f, 2a, b, d, f, g, 3d, f, g, 4b, c, e, 5a–c, 6f; Supplementary
Figs. 2a, 3e–h, 4d, 5a, e, h, i, and 6b can found in the source data ﬁle.
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